Werewolf Therapeutics Q1 net loss $15.3M; Jazz Pharma license and $40M loan extend runway

Werewolf Therapeutics, Inc.

2022-Q1 EPS reported -$0.56

Net loss of $15.3M in Q1 2022 vs. $7.4M year-ago; R&D expense rose to $10.9M from $4.8M.
Cash and equivalents of $143.7M at March 31, 2022; plus Jazz $15M upfront and $20M loan tranche, runway through Q4 2023.
Entered exclusive global license with Jazz for WTX-613; $15M upfront, up to $1.26B milestones plus mid-single-digit royalties.
IND submissions for WTX-124 and WTX-330 on track; preclinical data presented at AACR 2022.
Closed $40M term loan with Pacific Western Bank; $20M available upon two IND acceptances by March 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.